CRISPR

CRISPR-Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9. The system was first observed in bacteria, where it functions as an adaptive immune defense against invading viruses. Researchers later identified CRISPR sequences in archaea as well, revealing a widespread natural mechanism that scientists have adapted for laboratory genetic engineering knockins and knockouts applications.

When viral DNA enters a bacterium, it is processed into smaller fragments and inserted into a CRISPR locus in the bacterial genome. Upon transcription, these fragments associate with tracrRNAs and form complexes with Cas9 protein. The resulting guide RNAs recognize and direct Cas9 to viral DNA, which is then cleaved and destroyed, protecting the bacterium from infection.

Scientists synthesize guide RNAs that mimic the natural tracrRNA and CRISPR RNA, targeting a specific gene of interest. These guide RNAs are introduced into cells along with Cas9 protein. The guide RNA directs Cas9 to the target DNA sequence, where it cleaves the DNA. The cell's repair machinery then reconnects the cut ends, effectively inactivating the target gene or allowing insertion of new genetic material.

Once the target DNA region is removed by Cas9, the cell's machinery reconnects the cut ends through its natural DNA repair processes. The cell may insert or delete random nucleotides during repair, rendering the target gene inactive. Alternatively, researchers can introduce a customized DNA template that guides the repair machinery to replace the excised sequence with a corrected or new genetic sequence.

CRISPR-Cas9 could potentially cure genetic disorders such as hemophilia and sickle cell anemia by replacing mutated genes with normal copies. Researchers can use the system to knock out disease-causing genes or insert therapeutic sequences. These genome editing capabilities make CRISPR-Cas9 a powerful tool for developing gene therapy disease intervention treatments, though ethical and safety considerations must be carefully evaluated.

A major ethical debate surrounds embryo editing with CRISPR-Cas9, particularly following a controversial claim of genome-edited babies. Scientists have expressed concerns about off-target genomic effects, where Cas9 may cut DNA at unintended locations. Many researchers consider human embryo editing premature given current safety limitations, and the global scientific community continues to debate appropriate guidelines for this powerful technology.

In bacteria, the natural CRISPR system captures viral DNA fragments into a CRISPR array and uses them to recognize and destroy future viral invaders. Scientists have modified this system by synthesizing artificial guide RNAs that target any gene of interest rather than only viral sequences. This adaptation allows researchers to employ CRISPR-Cas9 for precise genome editing across diverse applications beyond viral defense.